ストックスクリーナーアプリを入手
1.26
3.28%
0.04
プレマーケット:
1.28
0.02
+1.59%
前日終値:
$1.22
開ける：
$1.21
24時間の取引高:
2.72M
Relative Volume:
1.48
時価総額：
$89.60M
収益：
$391.70K
当期純損益:
$-52.34M
株価収益率:
-1.68
EPS:
-0.75
ネットキャッシュフロー:
$-45.92M
1週間 パフォーマンス:
+32.63%
1か月 パフォーマンス:
+103.72%
6か月 パフォーマンス:
+137.15%
1年 パフォーマンス:
-1.56%
1日の値動き範囲:
$1.15
$1.2964
1週間の範囲:
$0.9023
$1.2964
52週間の値動き範囲:
$0.2425
$1.47
Ovid Therapeutics Inc Stock (OVID) Company Profile
名前
Ovid Therapeutics Inc
セクター
電話
212-776-4381
住所
441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
OVID を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
OVID
Ovid Therapeutics Inc
|
1.26 | 86.75M | 391.70K | -52.34M | -45.92M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
389.08 | 99.27B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
586.96 | 62.28B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.18 | 59.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
707.96 | 43.34B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
300.14 | 36.72B | 3.81B | -644.79M | -669.77M | -6.24 |
Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-08 | 再開されました | B. Riley Securities | Buy |
| 2024-06-18 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-04-30 | 開始されました | B. Riley Securities | Buy |
| 2024-04-29 | 開始されました | H.C. Wainwright | Buy |
| 2024-04-05 | 開始されました | Wedbush | Outperform |
| 2023-12-21 | 開始されました | BTIG Research | Buy |
| 2023-10-13 | 開始されました | Oppenheimer | Outperform |
| 2021-04-20 | ダウングレード | Cantor Fitzgerald | Buy → Neutral |
| 2021-03-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-12-02 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-12-02 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-04 | 開始されました | RBC Capital Mkts | Outperform |
| 2018-04-20 | 開始されました | Ladenburg Thalmann | Buy |
すべてを表示
Ovid Therapeutics Inc (OVID) 最新ニュース
Quantitative breakdown of Ovid Therapeutics Inc. recent moveWeekly Risk Summary & Weekly Setup with High ROI Potential - Newser
Custom watchlist performance reports with Ovid Therapeutics Inc.Wall Street Watch & Technical Entry and Exit Alerts - Newser
Key metrics from Ovid Therapeutics Inc.’s quarterly data2025 Macro Impact & Safe Entry Momentum Stock Tips - Newser
What machine learning models say about Ovid Therapeutics Inc.Quarterly Trade Report & Safe Entry Momentum Tips - Newser
Multi asset correlation models including Ovid Therapeutics Inc.July 2025 Decliners & Momentum Based Trading Signals - Newser
Using R and stats models for Ovid Therapeutics Inc. forecasting2025 Key Lessons & High Accuracy Investment Signals - Newser
Using Ichimoku Cloud for Ovid Therapeutics Inc. technicalsJuly 2025 Reactions & Free High Accuracy Swing Entry Alerts - Newser
Building trade automation scripts for Ovid Therapeutics Inc.July 2025 Trade Ideas & Fast Gaining Stock Reports - Newser
Identifying reversal signals in Ovid Therapeutics Inc.Inflation Watch & Community Shared Stock Ideas - Newser
Momentum divergence signals in Ovid Therapeutics Inc. chartJuly 2025 Action & Long-Term Growth Stock Strategies - Newser
Technical analysis overview for Ovid Therapeutics Inc. stockSell Signal & Safe Entry Trade Reports - Newser
What makes Ovid Therapeutics Inc. stock price move sharplyJuly 2025 Earnings & Reliable Momentum Entry Alerts - Newser
Key resistance and support levels for Ovid Therapeutics Inc.Bear Alert & Fast Moving Stock Trade Plans - Newser
Will Ovid Therapeutics Inc. price bounce be sustainableInsider Buying & Verified Entry Point Detection - Newser
Lucid Capital Initiates Ovid Therapeutics Inc. (OVID) at Buy with $5.50 Target - MSN
Full technical analysis of Ovid Therapeutics Inc. stockJuly 2025 Recap & AI Powered Buy and Sell Recommendations - Newser
Ovid Therapeutics Inc. recovery potential after sell offWeekly Gains Report & Verified Momentum Stock Alerts - Newser
What technical models suggest about Ovid Therapeutics Inc.’s comebackJuly 2025 Trade Ideas & Safe Capital Growth Plans - Newser
How hedge fund analytics apply to Ovid Therapeutics Inc. stockMarket Sentiment Review & Comprehensive Market Scan Reports - Newser
Has Ovid Therapeutics Inc. formed a bullish divergence2025 Dividend Review & Real-Time Volume Analysis Alerts - Newser
Multi factor analysis applied to Ovid Therapeutics Inc.Quarterly Market Summary & Consistent Growth Stock Picks - Newser
H.C. Wainwright reiterates Buy rating on Ovid Therapeutics stock at $1.50 - Investing.com Canada
Will Ovid Therapeutics Inc. outperform the market in YEARJuly 2025 Update & Safe Investment Capital Preservation Plans - sundaytimes.kr
Ovid Therapeutics (OVID): A High-Conviction Buy for Neurological Innovation and Market Breakthroughs - AInvest
What machine learning models say about Ovid Therapeutics IncJuly 2025 Sentiment & Fast Gain Swing Alerts - Newser
How high can Ovid Therapeutics Inc. stock go2025 Geopolitical Influence & Free Real-Time Volume Trigger Notifications - Newser
Technical Models Detect Momentum Build in Ovid Therapeutics Inc.2025 Market Sentiment & Fast Gain Swing Alerts - 더경남뉴스
Spotlight On 3 Promising Penny Stocks With Over $60M Market Cap - simplywall.st
Is Ovid Therapeutics Inc. Stock a Smart Buy in 2025 Investment Analysis InsideWeekly Stock Summary & High Accuracy Investment Entry Signals - Newser
Ovid Therapeutics Transfers Stock to Nasdaq Capital Market - MSN
BTIG Assigns Buy Rating to Ovid Therapeutics with $4 Price Target - AInvest
Is Ovid Therapeutics Inc. Forming a Bottom PatternJuly 2025 News Drivers & Low Risk Entry Point Tips - beatles.ru
Top Analysts Recommend 3 Strong Buys: Palo Alto Networks, Ovid Therapeutics, and Blaize Holdings - AInvest
Is Ovid Therapeutics Inc. stock poised for growth2025 Momentum Check & High Win Rate Trade Alerts - Newser
Ovid Therapeutics Inc (OVID) 財務データ
収益
当期純利益
現金流量
EPS
0.98%
8.06%
大文字化:
|
ボリューム (24 時間):